Intellectus Partners LLC Has $150,000 Stock Holdings in Affimed (NASDAQ:AFMD)

Intellectus Partners LLC boosted its holdings in shares of Affimed (NASDAQ:AFMD) by 34.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 126,414 shares of the biopharmaceutical company’s stock after acquiring an additional 32,053 shares during the period. Intellectus Partners LLC’s holdings in Affimed were worth $150,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in shares of Affimed in the third quarter valued at about $44,000. Point72 Asset Management L.P. raised its holdings in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the last quarter. Finally, FMR LLC raised its holdings in shares of Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Stifel Nicolaus lowered their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Wells Fargo & Company lowered their target price on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Affimed in a report on Tuesday, December 10th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Affimed has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Stock Performance

AFMD opened at $0.99 on Friday. The firm has a 50-day moving average of $1.09 and a 200 day moving average of $2.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. Affimed has a fifty-two week low of $0.92 and a fifty-two week high of $8.95.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.